I would add to the above that it's possibly the 'pharmacokinetics' of NNZ-2591 (bioavailability, stability, half-life), rather than it's mechanism of action, that has caused Jon to call it the "jewel in the crown" for Neuren.
It looks to me Neuren may have made some compromises to get Trofinitide to work. NNZ-2591 appears closer to the 'ideal' pharmacokinetics you'd want in an effective drug. If its half-life is longer than Trofinitide too then doubly so.
Neuren - where to from here ?, page-71
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.39 |
Change
0.050(0.26%) |
Mkt cap ! $2.476B | |||
| Open | High | Low | Value | Volume |
| $19.60 | $19.65 | $19.00 | $11.60M | 599.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $19.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.39 | 1004 | 3 |
View Market Depth
| Last trade - 16.10pm 06/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.31 |
Change
0.050 ( 0.06 %) |
||||
| Open | High | Low | Volume | ||
| $19.58 | $19.62 | $19.00 | 161547 | ||
| Last updated 15.59pm 06/06/2024 ? | |||||
| NEU (ASX) Chart |